ArticleBrain : a journal of neurology2026
White matter lesions disrupt cholinergic pathways important for cognition in Parkinson's disease.
Article in Brain : a journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
White matter lesions are associated with cognitive impairment in Parkinson's disease, but the underlying neurobiological mechanisms remain unclear. One hypothesis is that strategically located white matter lesions disrupt long-range white-matter pathways crucial for cognitive functioning, particularly cholinergic projections from the basal forebrain, contributing to cognitive decline. Using volumetric measures of basal forebrain nuclei (T1 MRI proxy for brain cholinergic projection nuclei), quantitative white matter lesions assessments (fluid-attenuated inversion recovery MRI), and a presynaptic cholinergic marker ([18F]-FEOBV PET), we tested a mechanistic model of white matter lesions effects on basal forebrain cholinergic projections and nuclei, and how these disruptions relate to cognition. We analysed data from 127 mid to advanced-stage patients with Parkinson's disease without dementia. Periventricular and deep white matter lesion burdens were quantified with the UBO Detector pipeline. Cognitive function was assessed across five domains using z-scores from a control group matched for age and education. Voxel-wise analyses examined associations between white matter lesion burden and cholinergic synaptic density, followed by mediation analyses testing whether cholinergic alterations mediated the relationship between white matter lesions and cognition, while correcting for sex, levodopa equivalent dose, and disease duration. Voxel-wise analyses revealed that higher periventricular lesions burden was associated with reduced [18F]-FEOBV uptake in an insular-limbic-frontal-cingulum cluster, while deep lesions showed more topographically limited associations that disappeared after adjusting for periventricular burden. Periventricular lesions affected lateral and external Ch4 cholinergic projection pathways (81%-88% of patients), more frequently than deep white matter lesions (25%-47% of patients), except for the external capsule, which was equally affected by both. Cognitive performance (global cognition, memory, executive function, and attention) was associated with both periventricular lesion burden and [18F]-FEOBV uptake within the insular-limbic-frontal-cingulum cluster, as well as with basal forebrain volume. Mediation analyses indicated that periventricular lesions had a direct effect on cortical terminal integrity ([18F]-FEOBV) and an indirect, presumably retrograde degeneration effect via basal forebrain atrophy. The effect of periventricular lesions on insular-limbic-frontal-cingulum cholinergic terminal density was a strong mediator of the association between lesion burden and cognitive performance. A weaker mediation effect via the basal forebrain emerged for global cognition, whereas mediation was more robust for memory and executive functioning. Our findings indicate that periventricular white matter lesions contribute to cognitive vulnerability in Parkinson's disease without dementia through impacts on basal forebrain cholinergic projections. White matter lesion burden may represent a mechanistically meaningful biomarker for predicting cognitive trajectories and informing targeted interventions in Parkinson's disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.